Company Description
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.
The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio.
It has 42 issued/allowed patents and 23 patent applications pending worldwide.
The company has a strategic collaboration agreement with Stryker Corporation for technology co-development.
Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
| Country | United States |
| IPO Date | Mar 25, 1992 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Harel Gadot |
Contact Details
Address: 25 Recreation Park Drive Hingham, Massachusetts United States | |
| Website | https://www.microbotmedical.com |
Stock Details
| Ticker Symbol | MBOT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000883975 |
| CUSIP Number | 59503A204 |
| ISIN Number | US59503A2042 |
| Employer ID | 94-3078125 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Harel Gadot | Co-Founder, President, Chief Executive Officer & Chairman |
| Dr. Simon Sharon MBA, MSc | Chief Technology Officer & GM of Microbot Israel |
| Rachel Vaknin | Chief Financial Officer |
| Dr. Juan Diaz-Cartelle | Chief Medical Officer |
| Yoseph Bornstein | Co-Founder & Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | SCHEDULE 13G | Filing |
| Jan 10, 2025 | SCHEDULE 13G | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 424B5 | Filing |
| Jan 07, 2025 | 8-K | Current Report |
| Jan 07, 2025 | 424B5 | Filing |
| Jan 06, 2025 | 424B3 | Filing |
| Jan 06, 2025 | 424B3 | Filing |
| Jan 06, 2025 | 8-K | Current Report |
| Dec 30, 2024 | 8-K | Current Report |